HUTCHMED (China) Limited American Depositary Shares

HUTCHMED announced positive Phase II pivotal trial results for fanregratinib (HMPL-453) in treating advanced intrahepatic cholangiocarcinoma patients with FGFR2 fusion/rearrangement. The study achieved a 42.5% objective response rate, 6.9-month median duration of response, and 16.6-month median overall survival, with a manageable safety profile. ...

HUTCHMED announced positive Phase III results for sovleplenib (HMPL-523) in treating warm antibody autoimmune hemolytic anemia (wAIHA). The drug demonstrated a 66% durable response rate versus 15% for placebo and showed rapid hemoglobin response with a favorable safety profile. China's NMPA accepted the New Drug Application for priority review in...

Johnson & Johnson announced that IMAAVY (nipocalimab-aahu) achieved its primary endpoint in the Phase 2/3 ENERGY study for warm autoimmune hemolytic anemia (wAIHA). Patients receiving the 30 mg/kg dose were three times more likely to achieve durable hemoglobin improvements compared to placebo over 24 weeks. The drug demonstrated rapid onset of ef...

HUTCHMED announced that new and updated data from several studies will be presented at the AACR Annual Meeting 2026 in San Diego. Preclinical data for HMPL-A580, a first-in-class PI3K/PIKK-EGFR Antibody-Targeted Therapy Conjugate, showed robust anti-tumor effects with excellent selectivity and favorable pharmacokinetic properties. Updated results...

HUTCHMED has initiated a Phase III clinical trial of HMPL-760 combined with R-GemOx in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in China. The trial will enroll approximately 240 patients and follows encouraging Phase II results showing improvements in overall response rate, complete response rate, progression-free s...